The article describes that the bacterium Neisseria gonorrhoeae persistently develops resistance to the antibiotics used, which makes the treatment of gonorrhea more difficult. The discovery of new antimicrobial drugs to treat gonorrhea is identified as a global priority. Antimicrobial-resistant gonorrhea is identified as an urgent threat to public health. Ceftriaxone is currently the main recommended treatment regimen for gonorrhea worldwide. Reports from China, Cambodia, Vietnam, and the United Kingdom indicate reduced susceptibility to ceftriaxone and occasional treatment failures with the drug. These findings threaten ceftriaxone's status as a key drug in the treatment of gonorrhea. The article highlights the need for expanded global antimicrobial surveillance to track resistance trends. In this context, he comments that the new oral treatment with zoliflodacin shows benefit in the treatment of uncomplicated gonorrhea.